Lyell Immunopharma News and Activities

Lyell Immunopharma is a company listed under the stock ticker LYEL (US).

Acquisition, funding and merger involving Lyell Immunopharma.

• Lyell Immunopharma has acquired ImmPACT Bio (posted on November 29 2024).

View the org chart displaying its 27 main executives

Most searched biographies at Lyell Immunopharma

• Lynn Seely, Director, President and Chief Executive Officer
• Mark Bachleda, Independent Director
• Catherine Friedman, Director

Popular executive movements at Lyell Immunopharma

• Smital Shah has joined the company as Chief Financial and Business Officer  (posted on March 9 2026).
• Ellen Rose, Senior Vice President, Investor Relations and Communications, has left the company  (posted on January 9 2026).
• Charles Newton, Chief Financial Officer, will leave the company on Oct. 31, 2025  (posted on September 17 2025).

Create your alert
to follow the executive moves at Lyell Immunopharma.

Lyell Immunopharma has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Lyell Immunopharma

• Lyell Immunopharma Announces Participation in May Investor Conferences | Lyell Immunopharma, Inc.
• Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 | Lyell Immunopharma, Inc.
• Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference | Lyell Immunopharma, Inc.
• Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results | Lyell Immunopharma, Inc.
• Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer  | Lyell Immunopharma, Inc.
• Lyell Immunopharma Announces Participation in March Investor Conferences | Lyell Immunopharma, Inc.
• Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | Lyell Immunopharma, Inc.
• Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | Lyell Immunopharma, Inc.
• News Releases | Lyell Immunopharma, Inc.
• News Releases | Lyell Immunopharma, Inc.
• View more press releases Close

Social media about Lyell Immunopharma

• Lyell Immunopharma on Wikipedia, Google News & Yahoo Finance
• Lyell Immunopharma on LinkedIn, X (Twitter) & YouTube